HHS Public Access

Author manuscript

Breast Cancer Res Treat. Author manuscript; available in PMC 2022 December 01.

Published in final edited form as:

Breast Cancer Res Treat. 2017 June ; 163(3): 639–640. doi:10.1007/s10549-017-4250-4.

Erratum to: ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling

Luca Gelsomino[1], **Guowei Gu**[2], **Yassine Rechoum**[2], **Amanda R. Beyer**[2], **Sasha M. Pejerrey**[2], **Anna Tsimelzon**[2], **Tao Wang**[2], **Kenneth Huffman**[3], **Andrew Ludlow**[3], **Sebastiano Andò**[1], **Suzanne A. W. Fuqua**[2,4]

[1]Department of Pharmacy, Health, and Nutritional Sciences, University of Calabria, Arcavacata di Rende, Cosenza, Italy

[2]Lester & Sue Smith Breast Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA

[3]Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, USA

[4]Dan L Duncan Cancer Center, Houston, TX, USA

In the original publication of the article, the panel for estrogen receptor (ER) in Fig. 2c was incorrectly published. The corrected Fig. 2 is given in this erratum.

✉ Suzanne A. W. Fuqua, sfuqua@bcm.edu.



Fig. 2.

IGF-1 signaling pathway activation in HBD-ESR1 mutants. **a** Ingenuity pathway analysis (IPA) to identify activation of signaling pathways in mutant MCF-7 versus ZR-75B. **b** Total cellular extracts were analyzed for phosphorylation and expression of ER, IGF1Rβ, IRS-1, and mTOR; GAPDH was used as a loading control. Immunoblots show a representative example of three experiments. **c** Total cellular extracts were analyzed for phosphorylation and expression of ERα, IGF1Rβ, IRS-1, and mTOR; GAPDH was used as a loading control. Immunoblots show a representative example of three different experiments